NHS to receive £8m from Aspen over anti-competitive practices
15-08-2019
CMA accuses hydrocortisone suppliers of anti-competitive behaviour
04-03-2019
12-03-2020
StockStudio / Shutterstock.com
The UK Competition and Markets Authority (CMA) has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Phenytoin, pricing, CMA, Competition and Markets Authority, epilepsy, Pfizer, Flynn Pharma, Competition Appeal Tribunal